The exploratory clinical trial to evaluate the efficacy of [11C]K-2 in stroke patients under rehabilitation. - The evaluation of [11C]K-2 in rehabilitation process.

Yokohama City University0 sites20 target enrollmentJanuary 4, 2018

Overview

No summary available.

Registry

who.int

Start Date

January 4, 2018

End Date

March 19, 2020

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\) All patients with the psychiatric disorders which demand the administration of anti depressants such as tricyclic, tetracyclic, SSRI, SNRI and NaSSa 2\) All patients with cognitive disorders; the score of Mini\-Mental State Examination under 23 3\) All patients who had other neurologic and spinal diseases which affect motor and sensory function in upper and lower limb. 4\) All patients who participated to other clinical trial (excluded observational study) in 6 months before their consent to this trial. 5\) All patients who had contraindication to MRI and/or had the specific lesion other than cerebral infarction 6\) All patients with the hemodialysis treatment 7\) All patients with liver dysfunction (AST over 150 IU/ml and/or ALT over 150 IU/m) in screening phase 8\) All patients with renal dysfunction (eGFR over 60\) in screening phase 9\) All patients with current or past epilepsy 10\) All patients with the administration of anti epileptic drugs 11\) All patients planned to under take the constraint\-induced movement therapy and rTMS therapy in their admission 12\) All patients who were breast\-feeding, pregnant or suspected pregnant 13\) All patients who desire to be pregnant and can not contraception between the inclusion and the 2nd PET study 14\) All patients judged to be unsuitable to this trial by the chief and/or other doctors in the team